In this OncLive® Insights program, Dr. Joshua Richter and Dr. Doris Hansen discuss the evolving role of CAR T-cell therapy in early relapsed/refractory multiple myeloma, with a focus on treatment sequencing, patient selection, bridging therapy, and emerging cellular therapy approaches. The experts examine how the expanding availability of BCMA-directed CAR T-cell therapies and bispecific antibodies is influencing treatment decisions at first relapse, including considerations around using CAR T-cell therapy earlier in the disease course. They discuss the importance of early referral to cellular therapy centers, appropriate patient selection, and disease control before CAR T-cell infusion. The conversation also explores how bridging therapy can help optimize patients for treatment, including strategies to balance disease control, T-cell fitness, efficacy, and toxicity risk. Dr. Richter and Dr. Hansen further address treatment sequencing following CAR T-cell therapy and consider emerging approaches such as dual-target CAR T-cell therapies, GPRC5D-directed cellular therapies, in vivo CAR T-cell platforms, and allogeneic CAR T-cell therapies.
Dr. Joshua Richter introduces the discussion with Dr. Doris Hansen, outlining the evolving role of CAR T-cell therapy in early relapsed/refractory multiple myeloma, with a focus on treatment sequencing, patient selection, bridging therapy, toxicity management, and emerging cellular therapies.
Dr. Joshua Richter discusses the rationale behind prioritizing BCMA-directed CAR T-cell therapy before BCMA-directed bispecific antibodies in eligible patients with multiple myeloma, reflecting current International Myeloma Working Group considerations.
